Clinical Trial Applications: Filter, Search, and view applications
# | Protocol No | Study Title | Investigator(s) & Site(s) | |
---|---|---|---|---|
486. |
ECCT/09/09/02 | MAL-58 Study: Protocol no. 112745: SAFETY AND IMMUNOGENICITY STUDY OF GSK BIOLOGICALS\' Plasmondium falciparum MALARIA VACCINE 257049 ADMINISTERED TO HIV INFECTED INFANTS AND CHILDREN SAFETY AND IMMUNOGENICITY STUDY OF GSK BIOLOGICALS' Plasmondium falciparum MALARIA VACCINE 257049 ADMINISTERED TO HIV INFECTED INFANTS AND CHILDREN |
Principal Investigator(s) 1. LUCAS OTIENO TINA 2. MARY HAMEL Site(s) in Kenya 1. KEMRI-CDC, (Siaya county) 2. KEMRI-WRP (Kisumu county) |
View |
487. |
ECCT/11/01/02 | EARNEST EARNEST : Europe -Africa Research Network for Evaluation of Second-line Therapy |
Principal Investigator(s) 1. Abraham Mosigisi Siika Site(s) in Kenya Moi University Clinical Research Centre |
View |
488. |
ECCT/13/05/01 | Use of the Shang Ring device in all four childhood age groups in the African population |
Principal Investigator(s) 1. Quentin David Awori Site(s) in Kenya Homa Bay District Hospital |
View |
489. |
ECCT/13/04/02 | XANTUS EMEA-LA. Xarelto® on prevention of stroke and non-central nervous system systemic embolism in patients with non-valvular atrial fibrillation in Eastern EU, Middle East, Africa (EMEA) and Latin America (LATAM): A non-interventional study |
Principal Investigator(s) 1. Dr Charles Muthui Kariuki Site(s) in Kenya Nairobi Cardiovascular Clinic |
View |
490. |
ECCT/12/11/02 | Not provided A5297: An Open-Label, Proof of Concept, Randomized Trial Comparing a LPV/r-Based to an nNRTI-Based Antiretroviral Therapy Regimen for Clearance of Plasmodium falciparum Subclinical Parasitemia in HIV-infected Adults with CD4+ Counts >200 and <350 cells/mm3 |
Principal Investigator(s) 1. Abraham Mosigisi Siika Site(s) in Kenya 1. Moi University Clinical Research Centre (Uasin Gishu county) |
View |